What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hypertrophic Cardiomyopathy
- Main trialPhase 2
- “This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).”In the company’s words, NCT06347159 on ClinicalTrials.gov
Other drugs for Hypertrophic Cardiomyopathy
- SotagliflozinLexicon Pharmaceuticals · Phase 3
- HRS-1893Hengrui · Phase 3
- BHB-1893Braveheart Bio, Inc. · Phase 3
- AficamtenCytokinetics · Phase 2/3
- BAY3723113Bayer · Phase 3
- NinerafaxstatImbria Pharmaceuticals, Inc. · Phase 2
Coming up1
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Dec 2027 | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) | |
| Phase 1Completed | 23 May 2024 | A Study of EDG-7500 in Healthy Adults | |
| Phase 1Completed | 17 Jan 2025 | A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 | |
| Phase 1Completed | 22 Dec 2025 | A Study to Evaluate EDG-7500 in People With Renal Impairment | |
| Phase 1Completed | 7 Apr 2026 | A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment | |
| Phase 1Completed | 1 Jun 2026 | A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026